Clinical pathways of patients with lung cancer followed in the Inspire Program in Botucatu, Brazil: an exploratory study
DOI:
https://doi.org/10.21115/JBES.v18.p76-85Palavras-chave:
Câncer de pulmão, Rastreamento, Jornada assistencial, Gestão em saúdeResumo
Introdução: A análise de percursos assistenciais em câncer de pulmão permite compreender a organização do cuidado e identificar oportunidades de melhoria no sistema de saúde. Objetivo: Este estudo teve como objetivo analisar, de forma exploratória, os percursos clínicos de pacientes atendidos pelo Programa Inspire, em Botucatu, Brasil. Métodos: Estudo retrospectivo com dados de pacientes acompanhados entre janeiro de 2023 e outubro de 2024. Foram analisados registros clínicos e administrativos por meio de técnicas de mineração de processos, permitindo a avaliação da frequência de atividades e dos intervalos entre etapas do cuidado. Resultados: Foram incluídos oito pacientes (idade média 63,5 anos; 62,5% mulheres), com predominância de diagnóstico em estágios avançados (37,5% estágio IV). Antes do tratamento, destacaram-se atendimentos na atenção primária (17,8%) e exames laboratoriais (13,4%). Após o diagnóstico, exames laboratoriais (22,9%) e radioterapia (16,6%) foram mais frequentes. Observou-se variação dos percursos conforme o estadiamento, com maior uso de cirurgia nos estágios iniciais e terapias combinadas nos avançados. Houve heterogeneidade nos tempos entre etapas do cuidado. Conclusão: Os percursos assistenciais evidenciam elevada complexidade e variabilidade, reforçando o potencial da mineração de processos para análise organizacional do cuidado em oncologia.
Downloads
Referências
Fares, A.F., et al., Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies. Lancet Public Health, 2023. 8(9): p. e691-e700.
Dickson, J.L., et al., Uptake of invitations to a lung health check offering low-dose CT lung cancer screening among an ethnically and socioeconomically diverse population at risk of lung cancer in the UK (SUMMIT): a prospective, longitudinal cohort study. The Lancet Public Health, 2023. 8(2): p. e130-e140.
Tammemägi, M.C., et al., USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. The Lancet Oncology, 2022. 23(1): p. 138-148.
de Koning, H.J., et al., Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med, 2020. 382(6): p. 503-513.
Arruda, G.V., et al., Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system. The Lancet Regional Health - Americas, 2022. 14: p. 100329.
Byers, L.A. and J.V. Heymach, Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer, 2007. 8 Suppl 2: p. S79-85.
Zhang, Y., et al., Understanding the patient journey to diagnosis of lung cancer. BMC Cancer, 2021. 21(1): p. 402.
Raeth, J., et al., Different pathways to lung cancer diagnosis in a real-life setting. Respir Med Res, 2024. 86: p. 101108.
Woodard, G.A., K.D. Jones, and D.M. Jablons, Lung Cancer Staging and Prognosis. Cancer Treat Res, 2016. 170: p. 47-75.
Au, P.C.M., et al., The trends in lung cancer prevalence, incidence, and survival in Hong Kong over the past two decades (2002–2021): a population-based study. The Lancet Regional Health - Western Pacific, 2024. 45: p. 101030.
National Lung Screening Trial Research, T., et al., Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011. 365(5): p. 395-409.
Santos, R.S.d., et al., Do Current Lung Cancer Screening Guidelines Apply for Populations With High Prevalence of Granulomatous Disease? Results From the First Brazilian Lung Cancer Screening Trial (BRELT1). The Annals of Thoracic Surgery, 2016. 101(2): p. 481-488.
Hochhegger, B., et al., Challenges of Implementing Lung Cancer Screening in a Developing Country: Results of the Second Brazilian Early Lung Cancer Screening Trial (BRELT2). JCO Glob Oncol, 2022. 8: p. e2100257.
Svartman, F.M., et al., Lung cancer screening with low-dose CT integrated with pulmonary care in a public hospital in southern Brazil: results from the first 712 patients. Jornal Brasileiro de Pneumologia, 2022. 48(05): p. e20220146.
Sharman Moser, S., et al., Mapping the patient journey and treatment patterns in early-stage (stage I-III) non-small cell lung cancer. Cancer Epidemiol, 2024. 93: p. 102678.
Kourlaba, G., et al., Lung cancer patients' journey from first symptom to treatment: Results from a Greek registry. Cancer Epidemiol, 2019. 60: p. 193-200.
Raëth, J., et al., Different pathways to lung cancer diagnosis in a real-life setting. Respiratory Medicine and Research, 2024. 86: p. 101108.
Dickson, N.R., et al., Impact of clinical pathways on treatment patterns and outcomes for patients with non-small-cell lung cancer: real-world evidence from a community oncology practice. J Comp Eff Res, 2022. 11(8): p. 609-619.
Zhi, X.Y., et al., Clinical pathway for surgical treatment of primary lung cancer (2012 Edition). J Thorac Dis, 2012. 4(6): p. 671-5.
Wahla, A.S., et al., The Journey for Lung Cancer Screening where we Stand Today. The Open Respiratory Medicine Journal, 2022. 16.
Maiga, A.W., et al., Timeliness of Care and Lung Cancer Tumor-Stage Progression: How Long Can We Wait? The Annals of Thoracic Surgery, 2017. 104(6): p. 1791-1797.
Souza, J.A.d.M., et al., Factors associated with time to initiate lung cancer treatment in Minas Gerais, Brazil. Ciência & Saúde Coletiva, 2022. 27: p. 1133-1146.
Muslim, Z., et al., Increasing Time-to-Treatment for Lung Cancer: Are We Going Backward? The Annals of Thoracic Surgery, 2023. 115(1): p. 192-199.
Blanco-Villar, M.L., et al., Analyzing diagnostic and treatment wait times for lung cancer Patients: Key insights from a provincial registry study. Lung Cancer, 2024. 194: p. 107867.
Hall, H., et al., Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review. Thorax, 2022. 77(8): p. 762.
Kowalczyk, A. and J. Jassem, Multidisciplinary team care in advanced lung cancer. Translational Lung Cancer Research, 2019. 9(4): p. 1690-1698.
Blum, T.G., et al., European Respiratory Society guideline on various aspects of quality in lung cancer care. European Respiratory Journal, 2023. 61(2): p. 2103201.
Roetzheim, R.G., et al., Influence of primary care on breast cancer outcomes among Medicare beneficiaries. Ann Fam Med, 2012. 10(5): p. 401-11.
Tsui, J., et al., Understanding primary care-oncology relationships within a changing healthcare environment. BMC Family Practice, 2019. 20(1): p. 164.
Qiao, E.M., et al., Association Between Primary Care Use Prior to Cancer Diagnosis and Subsequent Cancer Mortality in the Veterans Affairs Health System. JAMA Network Open, 2022. 5(11): p. e2242048-e2242048.
Rubin, G., et al., The expanding role of primary care in cancer control. The Lancet Oncology, 2015. 16(12): p. 1231-1272.
Kurniati, A.P., et al., Process Mining to Explore Variations in Endometrial Cancer Pathways from GP Referral to First Treatment. Stud Health Technol Inform, 2021. 281: p. 769-773.
Marzano, L., et al., Application of Process Mining for Modelling Small Cell Lung Cancer Prognosis. Stud Health Technol Inform, 2023. 302: p. 18-22.
Wicky, A., et al., Interactive process mining of cancer treatment sequences with melanoma real-world data. Front Oncol, 2023. 13: p. 1043683.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Jornal Brasileiro de Economia da Saúde
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Esta licença permite que os usuários distribuam, remixem, adaptem e criem obras derivadas a partir do material em qualquer meio ou formato, exclusivamente para fins não comerciais e desde que seja feita a devida atribuição ao criador. A licença CC BY-NC inclui os seguintes elementos:
BY: É necessário dar crédito ao criador.
NC: Somente usos não comerciais da obra são permitidos.
